Compare GSIW & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSIW | TELA |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 37.5M |
| IPO Year | 2022 | 2019 |
| Metric | GSIW | TELA |
|---|---|---|
| Price | $30.02 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 2.2K | ★ 199.0K |
| Earning Date | 08-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $80,275,000.00 |
| Revenue This Year | N/A | $10.23 |
| Revenue Next Year | N/A | $14.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $0.05 | $0.50 |
| 52 Week High | $36.90 | $2.19 |
| Indicator | GSIW | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 65.93 | 62.28 |
| Support Level | $0.11 | $0.98 |
| Resistance Level | $32.25 | $1.24 |
| Average True Range (ATR) | 0.79 | 0.15 |
| MACD | -0.62 | 0.04 |
| Stochastic Oscillator | 31.93 | 66.83 |
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.